Loading...
XSTOCOMBI
Market cap4mUSD
Dec 23, Last price  
2.58SEK
1D
-5.15%
1Q
5.74%
Jan 2017
-93.84%
IPO
-97.55%
Name

Combigene AB

Chart & Performance

D1W1MN
XSTO:COMBI chart
P/E
—
P/S
9.21
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
70.17%
Rev. gr., 5y
268.62%
Revenues
6m
-79.23%
000003,000,0008,14614,986,02110,827,63784,041,57126,699,2825,544,117
Net income
-36m
L+564.56%
-11,808-27,495-960,503-6,468,979-8,666,376-8,958,133-13,146,068-17,839,303-30,774,86120,964,915-5,366,787-35,665,403
CFO
-31m
L+83.35%
59,208-272,155-620,669-6,285,516-8,808,579-9,527,453227,598-21,604,678-38,345,63822,114,817-16,665,683-30,557,123
Earnings
May 23, 2025

Profile

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
URL
https://combigene.com/
IPO date
May 25, 2015
Employees
10
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,544
-79.23%
26,699
-68.23%
84,042
676.18%
Cost of revenue
26,835
45,900
123,468
Unusual Expense (Income)
NOPBT
(21,291)
(19,200)
(39,427)
NOPBT Margin
Operating Taxes
(790)
2,358
Tax Rate
NOPAT
(21,291)
(18,410)
(41,785)
Net income
(35,665)
564.56%
(5,367)
-125.60%
20,965
-168.12%
Dividends
Dividend yield
Proceeds from repurchase of equity
65,881
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(101,445)
(131,777)
(136,744)
Cash flow
Cash from operating activities
(30,557)
(16,666)
22,115
CAPEX
(109)
(148)
Cash from investing activities
(989)
(148)
Cash from financing activities
65,881
FCF
(20,800)
(19,751)
(41,785)
Balance
Cash
101,440
131,777
136,744
Long term investments
5
Excess cash
101,168
130,442
132,542
Stockholders' equity
(107,667)
(72,002)
(65,845)
Invested Capital
224,124
224,047
224,103
ROIC
ROCE
EV
Common stock shares outstanding
19,801
19,801
17,311
Price
Market cap
EV
EBITDA
(20,961)
(16,606)
(36,832)
EV/EBITDA
Interest
5
2
Interest/NOPBT